LHF-535 是一种抗病毒剂，对 Lassa，Machupo，Junin，VSVg 病毒的 EC50 分别为<1 μm，<1 μm 和 1-10 μm，详细信息请参考专利文献 wo2012006552a1 中的化合物 1。
货号:ajcx38718
CAS:1450929-77-7
分子式:C27H28N2O2
分子量：412.52
溶解度:DMSO : 96.67 mg/mL (234.34 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of<1 μM,<1 μM,<1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively[1].

LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535 inhibits Lassa GP-pseudotyped lentivirus with an IC50 of 0.1-0.3 nM[2].

LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver[2]. An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection, demonstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice[2].

[1]. Dongcheng Dai, et al. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2.
[2]. Madu IG, et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439.